Sarah Meyer presentations to ACIP

One might expect the Director of the US CDC’s Immunization Safety Office to have detailed knowledge of Toxicology of all ingredients, "adjuvants" and contaminants of Jabs - perhaps she does?

Here is Sarah A Meyer.

She produced a 41 slide presentation to the NEW ACIP on 25 June 2025.¹

Sarah says Myocarditis the only “minor” worry

She must take the NEW ACIP for Fools.

Here is her slide claiming the CDC actively looked for signals for 65 of the ~10,000 different types of Adverse Events published by Pfizer in the 393-page list known as PSUR3 (Periodic Safety Update Report3 ) - a document she hopes is not mentioned in the current hearings. It provides a 393-page list of Adverse Events that Pfizer was mandated to report in order to be given Emergency Use Authorization.

Download it from my earlier article.²

There was another PSUR3 Appendix listing the Deaths from these Adverse Events by age group.

Sarah Meyer on her Slide 19 uses artistic skill to illustrate just 8 Harms, all of which can be Lethal. Note she cites “and CDC unpublished data” in fine print.

I could go through the rest of her junk NEW ACIP presentation, but it would be a waste of time. You can download it along with others at the ACIP website.³

Let’s look at some of her earlier publications.

Sarah Meyer on Novavax

In November 2022 she and numerous colleagues published Interim Guidelines for this Jab.⁴

She mentioned the Matrix-M adjuvant that I have mentioned.⁵

But she was more interested in marketing Novavax.

As of May 2022, an estimated 13.9% of persons aged ≥18 years in the United States remained unvaccinated against COVID-19 (10). The availability of a COVID-19 vaccine that uses more traditional vaccine technology provides an additional option for unvaccinated persons.

Recent data reflect some interest in protein-based adjuvanted vaccines such as the Novavax COVID-19 vaccine (2). A survey designed to assess vaccination intentions for adjuvanted or nonadjuvanted protein-based COVID-19 vaccines among unvaccinated Americans conducted during January–February 2022 found that 16.0% of unvaccinated adults said that they “probably” or “definitely” would get an adjuvanted protein-based vaccine, with significantly lower intent among non-Hispanic White persons (9.6%) than among non-Hispanic Black or African American (20.1%) and Hispanic persons (19.5%), and with significantly higher intent among men (21.8%) than among women (11.9%) (2).

Sarah Meyer Loves Bivalent Booster Jabs

In October 2022, she reported on Bivalent Booster Jabs in a pointless attempt to cope with rapid mutation of the virus.⁶ Note that in this report, one of her co-authors was Endotoxin Expert Helen Kiepp Talbot, recently sacked by RFK Jr.⁷

Sarah Meyer was co-author of a 2020 report on a Covid19 variant outbreak.⁸

Cytomegalovirus in HIV Mothers and Infants

When working at Department of Medicine, Children’s Hospital Boston, Boston, Sarah Meyer was lead author of a paper that found antiretroviral drugs were ineffective.⁹

We examined the relationship between milk CMV and HIV-1 load (4–6 weeks postpartum) and the impact of antiretroviral treatment in 69 HIV-infected, lactating Malawian women and assessed the relationship between milk CMV load and postnatal growth in HIV-exposed, breastfed infants through six months of age. Despite an association between milk HIV-1 RNA and CMV DNA load (0.39 log10 rise CMV load per log10 rise HIV-1 RNA load, 95% CI 0.13–0.66), milk CMV load was similar in antiretroviral-treated and untreated women. Higher milk CMV load was associated with lower length-for-age (−0.53, 95% CI: −0.96, −0.10) and weight-for-age (−0.40, 95% CI: −0.67, −0.13) Z score at six months in exposed, uninfected infants. As the impact of maternal antiretroviral therapy on the magnitude of postnatal CMV exposure may be limited, our findings of an inverse relationship between infant growth and milk CMV load highlight the importance of defining the role of perinatal CMV exposure on growth faltering of HIV-exposed infants.

Meningococcal Jabs

Sarah Meyer promotes Meningococcal Jabs in Africa.¹⁰

Tdap, MenACWY and HPV Jabs in Adolescents

Once again, measuring and promoting with no mention of Adverse Events.¹¹

Flu Jabs

Checking her wider activity in dangerous ineffective Jabs, but there could be another S Meyer as cited.¹²

Should RFK Jr. Sack Sara Meyer ?

1. Sarah Meyer, MD MPH, Director, CDC’s Immunization Safety Office. Update on CDC’s COVID-19 Vaccine Safety Monitoring.

2.

3. https://www.cdc.gov/acip/meetings/presentation-slides-june-25-26-2025.html

4. Evelyn Twentyman, Megan Wallace, Lauren E. Roper, Tara C. Anderson, Amy B. Rubis, Katherine E. Fleming-Dutra, Elisha Hall, Joy Hsu, Hannah G. Rosenblum, Monica Godfrey, W. Roodly Archer, Danielle L. Moulia, Laura Daniel, Oliver Brooks, H. Keipp Talbot, Grace M. Lee, Beth P. Bell, Matthew Daley, Sarah Meyer, Sara E. Oliver. 2022. Morbidity and Mortality Weekly Report. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022.

5.

6. Hannah G. Rosenblum, Megan Wallace, Monica Godfrey, Lauren E. Roper, Elisha Hall, Katherine E. Fleming-Dutra, Ruth Link-Gelles, Tamara Pilishvili, Jennifer Williams, Danielle L. Moulia, Oliver Brooks, H. Keipp Talbot, Grace M. Lee, Beth P. Bell, Matthew F. Daley, Sarah Meyer, Sara E. Oliver and Evelyn Twentyman. October 2022. Morbidity and Mortality Weekly Report. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.

7.

8. Smith-Jeffcoat, S. E., M. A. Pomeroy, S. Sleweon, S. Sami, J. N. Ricaldi, Y. Gebru, B. Walker, S. Brady, M. Christenberry, S. Bart, J. Vostok, S. Meyer, S. Seys, A. Markelz, N. Ditto, V. Newbern, F. J. Thomas, D. Thomas, E. Cabredo, S. Kellner, V. R. Brown, J. E. Tate, and H. L. Kirking. 2022. 'Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among Persons in a Social Network Attending a Convention - New York City, November 18-December 20, 2021', MMWR Morb Mortal Wkly Rep, 71: 238-42

9. Sarah A. Meyer, Daniel J. Westreich, Emily Patel, Elizabeth P. Ehlinger, Linda Kalilani, Rachel V. Lovingood, Thomas N. Denny, Geeta K. Swamy, and Sallie R. Permar. 2014. Postnatal Cytomegalovirus Exposure in Infants of Antiretroviral-Treated and Untreated HIV-Infected Mothers. Infectious Diseases in Obstetrics and Gynecology. 989721. http://dx.doi.org/10.1155/2014/989721

10. Meyer SA, Kambou JL, Cohn A, et al. 2015. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso-Implications for introduction of PsA-TT into the Expanded Programme on Immunization. Vaccine. 33(12):1492-8. doi: 10.1016/j.vaccine.2015.01.043

11. Tanja Y. Walker, Laurie D. Elam-Evans, James A. Singleton, David Yankey, Lauri E. Markowitz, Benjamin Fredua, Charnetta L. Williams, Sarah A. Meyer, Shannon Stokley. 2017. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2016. Morbidity and Mortality Weekly Report. 66(33):874-882.

12. Roggelin L, Vinnemeier CD, Meyer S, et al. 2015. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine - assessing the immunogenicity and safety in an open label, uncontrolled study. Human Vaccines and Immunotherapeutics. 11(10):2370-5. doi: 10.1080/21645515.2015.1064570.